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AbstrACt
Objectives To quantify the costs, benefits and cost-
effectiveness of three multipathogen point-of-care 
(POC) testing strategies for detecting common sexually 
transmitted infections (STIs) compared with standard 
laboratory testing.
Design Modelling study.
setting Genitourinary medicine (GUM) services in 
England.
Population A hypothetical cohort of 965 988 people, 
representing the annual number attending GUM services 
symptomatic of lower genitourinary tract infection.
Interventions The decision tree model considered 
costs and reimbursement to GUM services associated 
with diagnosing and managing STIs. Three strategies 
using hypothetical point-of-care tests (POCTs) were 
compared with standard care (SC) using laboratory-based 
testing. The strategies were: A) dual POCT for Chlamydia 
trachomatis (CT) and Neisseria gonorrhoeae (NG); B) 
triplex POCT for CT-NG and Mycoplasma genitalium (MG); 
C) quadruplex POCT for CT-NG-MG and Trichomonas 
vaginalis (TV). Data came from published literature and 
unpublished estimates.
Primary and secondary outcome measures Primary 
outcomes were total costs and benefits (quality-adjusted 
life years (QALYs)) for each strategy (2016 GB, £) and 
associated incremental cost-effectiveness ratios (ICERs) 
between each of the POC strategies and SC. Secondary 
outcomes were inappropriate treatment of STIs, onward 
STI transmission, pelvic inflammatory disease in women, 
time to cure and total attendances.
results In the base-case analysis, POC strategy C, a 
quadruplex POCT, was the most cost-effective relative to 
the other strategies, with an ICER of £36 585 per QALY 
gained compared with SC when using microcosting, and 
cost-savings of £26 451 382 when using tariff costing. 
POC strategy C also generated the most benefits, with 
240 467 fewer clinic attendances, 808 fewer onward 
STI transmissions and 235 135 averted inappropriate 
treatments compared with SC.
Conclusions Many benefits can be achieved by 
using multipathogen POCTs to improve STI diagnosis 
and management. Further evidence is needed on the 
underlying prevalence of STIs and SC delivery in the UK to 
reduce uncertainty in economic analyses.
IntrODuCtIOn
Continued high transmission rates of sexually 
transmitted infections (STIs) that cause treat-
able lower genital tract discharge syndromes 
(GDS) are a major public health concern. 
This causes significant reproductive-health 
long-term sequelae1–4 and frequently necessi-
tates empirical therapy to minimise treatment 
strengths and limitations of this study
 ► The main strength of this study is that it presents the 
first estimates of the potential public health impact 
of multipathogen point-of-care test strategies made 
possible by emerging diagnostic technologies.
 ► The model used inputs from multiple sources in-
cluding published studies, published data (for costs), 
national surveillance data plus expert opinion and 
incorporated uncertainty in multiple input param-
eters by using a second-order Monte Carlo proba-
bilistic sensitivity analysis and numerous scenarios 
were assessed in sensitivity analysis.
 ► The main limitations were the paucity of published 
data on treatment pathways including efficacy of 
treatment and gaps in treatment guidelines, which 
made building a representative standard care path-
way problematic. There were few published data for 
some input parameters, for example, the percentage 
of patients who are presumptively treated without a 
microbiological result, or the percentage returning to 
clinic after initial treatment.
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delay, which often results in misdirected treatment, poor 
antimicrobial stewardship and the spread of antimicro-
bial resistance.5 6 Among the common causes of GDS, 
there were 107 252 and 39 696 diagnoses of Chlamydia 
trachomatis (CT) and Neisseria gonorrhoeae (NG), respec-
tively, made in English genitourinary medicine (GUM) 
services in 2015,7 with smaller numbers of Trichomonas 
vaginalis (TV) and Mycoplasma genitalium (MG) diagnoses.
The decision to give empirical antimicrobial therapy 
in symptomatic patients is usually guided by results of 
immediate microscopy of genital discharge, but this has 
low sensitivity, missing up to half of NG/TV infections in 
women8 and particularly poor specificity for predicting 
CT or MG. Accurate routine diagnosis, which requires 
laboratory-based nucleic acid amplification tests (NAATs), 
can take up to 2 weeks for results to be processed and most 
GUM services do not routinely conduct NAATs for MG or 
TV. Many patients are presumptively treated with either 
azithromycin or doxycycline, which are effective against 
CT but respectively cure only two-thirds and one-third 
of MG infections9 and neither antimicrobial is effective 
against TV.9
Emerging technologies are being developed that 
allow rapid and accurate point-of-care tests (POCTs) 
for multiple STIs, solutions which could address these 
challenges and help improve patient and public health 
outcomes. However, health services are under increasing 
financial pressure, and implementing new technolo-
gies may be prohibitively costly for both providers and 
commissioners of healthcare. There is currently only 
one commercially available rapid NAAT for CT and NG, 
which has equivalent performance to laboratory NAATs 
(Cepheid GeneXpert).10 Previous economic evaluations 
of NAAT POCTs for CT and NG indicate that they are 
likely to provide a cost-effective strategy for screening 
GUM attendees.5 11 To inform decision making by groups 
developing multipathogen POCTs and clinics which 
would likely use such tests, we assessed costs, benefits 
and cost-effectiveness of three testing strategies using 
hypothetical NAAT POCTs for A) CT-NG, B) CT-NG-MG 
and C) CT-NG-MG-TV compared with laboratory-based 
CT-NG NAAT testing.
MethODs
Creating a model structure
A decision tree model was constructed using Micro-
soft Excel (V.2016) to simulate a hypothetical cohort 
of people with symptoms of a lower genitourinary tract 
infection attending English GUM services. The base-
case or primary analysis, using assumptions provided 
in online supplementary table 1, compared complete 
pathway costs of three point-of-care (POC) strategies with 
the current practice of using microscopy plus a labora-
tory CT-NG NAAT. The POC strategies used microscopy 
plus a hypothetical POCT that provides results in 30 min 
for A) CT-NG; B) CT-NG-MG; C) CT-NG-MG-TV. Micros-
copy was used in all POC strategies as it can detect other 
conditions and infections not covered by the POCTs, as 
well as diagnosing NG and TV. The strategies were chosen 
in response to recent developments in STI POCT tech-
nology, reflecting pathogen configurations and perfor-
mance characteristics.12 13
Outcomes
Primary outcomes were total costs and benefits, measured 
by quality-adjusted life years (QALYs) for each strategy 
and associated incremental cost-effectiveness ratios 
(ICERs, Eq. (1)) between each of the POC strategies and 
standard care (SC). The ICER provides information on 
the additional cost per unit of additional benefit between 
an option and the next less expensive alternative.
  ICERx =
CostPOCx−CostCurrent Practice
QALYPOCx−QALYCurrent Practice   (1)
Secondary outcomes assessed the wider health benefits 
and included inappropriate treatment of STIs (defined as 
unnecessary treatment of people with no STI plus incor-
rect treatment for people with an STI), onward transmis-
sion of the four STIs, pelvic inflammatory disease (PID), 
a serious complication of CT, NG and MG infections in 
women, time to cure and total GUM attendances.
Patient pathways
Three senior clinicians at St George’s University Hospi-
tals NHS Foundation Trust, London outlined current 
and hypothetical POC pathways for symptomatic patients 
(figure 1). We assumed that treatment pathways did not 
vary by subgroup but that MSM had diagnostic tests from 
three anatomical sites (genital, pharyngeal and rectal) at 
initial visit and MSW and women only had genital swabs. 
The model accounted for single or dual infections with 
NG, CT, MG and/or TV.
The cost of treating PID was included in the model but 
other long-term complications associated with STI infec-
tion (eg, infertility) and adverse drug events associated 
with treatment were not considered. The proportion of 
patients lost-to-follow-up (LTFU) was estimated. It was 
assumed that anyone remaining in follow-up consented 
to diagnostic testing and, if diagnosed, accepted treat-
ment. The decision framework assumed that individuals 
had a maximum of three follow-up visits and then exited 
the model. Drug resistance was not considered. The time 
horizon for the model was 56 days. It was assumed that 
treatment was started on the day of diagnosis.
epidemiology and clinical parameters
A short online survey, distributed to members of the 
British Association for Sexual Health and HIV (BASHH), 
was used to collect data on the percentage of patients 
attending GUM services that are symptomatic, the 
percentage of patients returning after initial visits as well 
as MG testing protocols, as limited data were available 
from published literature. The survey was completed by 
23 GUM clinicians, 10 from London and 13 from else-
where in the UK (see online supplementary table 2).
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The total annual number of people attending English 
GUM services for STI testing was obtained from national 
surveillance data (GUMCAD 2015 data).7 The number of 
GUM attendees who were symptomatic was then calcu-
lated using the median percentages reported in the clini-
cian survey (50% of 1 181 574 for women; 40% of 647 661 
for men-who-have-sex-with-women (MSW) and 50% of 
232 274 for men-who-have-sex-with-men (MSM)). The 
model simulated a total of 965 988 symptomatic attendees 
and by subgroup, 590 787 women, 259 064 MSW and 
116 137 MSM. We assumed that hypothetical POCTs had 
similar sensitivity and specificity to the best performing 
currently available CT-NG POCTs.10 The prevalence of 
CT, NG, MG and TV in GUM attendees (table 1) was 
estimated using published studies and preliminary find-
ings from the PRECISE study,14 a study evaluating POCTs 
conducted by St George’s, University of London and 
Public Health England.
Patient and public involvement
There was no involvement from patients or the public in 
the design of the evaluation.
Cost and utility parameters
All costs are given in 2015/2016 prices (GB, £) and 
inflated to 2015/2016 costs when based on previous esti-
mates using the Hospital and Community Health Services 
(HCHS) Inflation Indices 2015.15 The model consid-
ered two perspectives for costs: 1) costs to GUM services 
(microcosting) associated with testing and management 
of NG/CT/MG/TV infections plus the cost of treating 
PID16 and 2) National Health Service (NHS) tariff reim-
bursements clinics would receive based on attendances 
(table 2). Microcosting was calculated by adapting an 
existing pathway model17 and includes the cost of staff 
time, diagnostic kit, drugs and other consumables. The 
tariff, an estimated average first and follow-up attendance 
Figure 1 Simplified patient flow through the model. Standard care (SC): 50% of people not diagnosed with Neisseria 
gonorrhoeae (NG) or Trichomonas vaginalis (TV) by microscopy will be presumptively treated for Chlamydia trachomatis (CT). 
The treatment is effective against CT, 67% of Mycoplasma genitalium (MG)9 and against all other non-specific bacterial sexually 
transmitted infections (STIs) (ie, not CT/NG/MG/TV). We assume this treatment is not effective against TV or NG. Incorrectly 
treated patients with NG infection will be diagnosed by nucleic acid amplification test, and return (minus those lost-to-follow-up) 
to receive treatment. Other returning patients may receive presumptive treatment for MG and TV. Point-of-care (POC) strategy 
A: 50% of people not diagnosed by microscopy or point-of-care test (POCT) would be presumptively treated for MG and TV. 
We assume that this treatment is effective against CT, MG, TV and against all other non-specific bacterial STIs. We assume 
that this treatment is not effective against NG. Patients not initially presumptively treated but who return to the clinic are then 
presumptively treated with MG and TV treatment. POC strategy B: 50% of people not diagnosed by microscopy or POCT would 
be presumptively treated for TV. We assume this treatment is effective against TV, and against all other non-specific bacterial 
STIs. We assume this treatment is not effective against CT, MG or NG. POC strategy C: 100% of people who are not diagnosed 
by microscopy or POC would be presumptively treated using azithromycin. We assume this treatment is effective against CT, 
67% of MG9 and against all other non-specific bacterial STIs. We assume this treatment is not effective against TV or NG. If 
any treated patients return, they will be categorised as ‘investigate further’. The cost of the ‘investigate further’ is the cost of a 
standard return appointment that includes microscopy.
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Table 2 Model input parameters: costs and utilities
Utilities
  Asymptomatic health state 1.00 Assume an otherwise healthy 
population
  Symptomatic health state 0.93 Sri, 201626
  Waiting for diagnosis (symptomatic) health state 0.93 Assume the same as symptomatic Sri, 201626
  Treatment complete, that is, returned to asymptomatic state 1.00 Assume they return to 
asymptomatic
  PID diagnosis health state 0.80 Smith, 200833
Costs
  Tariff cost of initial visit plus treatment management £141.00 Draft National Tariff Payment 
System: 2015/2016
18
  Initial clinic visit of symptomatic patient (microcosting) £103.71 Patient pathway adapted from a 
previous model
Adams, 2014*17
  Management of STI (oral medication) on same day as 
assessment†‡
£29.19 Excludes drug cost Adams, 2014*17
  Management of STI (oral medication) at return visit after results†‡ £31.32 Excludes drug cost Adams, 2014* 17
  Management of STI (medication via injection) on same day as 
assessment‡
£43.79 Excludes drug cost Adams, 2014* 17
  Management of STI (medication via injection) on return visit after 
results‡
£44.32 Excludes drug cost and GC 
culture/typing lab processing
Adams, 2014*17
  Standard CT/NG NAAT laboratory diagnostic test§ £13.17 Adams, 2014*17
  POCT CT-NG§ £24.00 Assumption based on cost of 
products currently available
  POCT CT-NG-MG§ £29.00 Assumption based on cost of 
products currently available
  POCT CT-NG-MG-TV§ £34.00 Assumption based on cost of 
products currently available
  Tariff cost of return visit £110.00 Draft National Tariff Payment 
System: 2015/2016
18
  Return clinic visit of symptomatic patient (microcosting) £83.25 Patient pathway adapted from a 
previous model
Adams, 201417
  NG test of cure using standard NAAT laboratory test £41.73 Adams, 2014*17
  NG test of cure using POC A £55.93 Adams, 2014*17
  Cost of drug treatment (first line) for CT £1.20 Where 95% of patients receive 
1 g azithromycin and 5% receive 
doxycycline 100 mg twice daily for 
7 days
BNF, 201634
  Cost of drug treatment (first line) for NG £5.95 Single-dose ceftriaxone 500 mg 
deep intramuscular injection with 
single dose 1 g azithromycin
BNF, 201634
  Cost of drug treatment (first line) for MG £1.87 Doxycycline 100 mg twice daily 
for 7 days
BNF, 201634
  Cost of drug treatment (first line) for TV
£0.36
Metronidazole 2 g orally in a single 
dose
BNF, 201634
  Cost associated with treatment of short-term PID £180.52 Aghaizu, 201116
*Costs were inflated to 2015/2016 costs using the Hospital and Community Health Services Inflation Indices 2015 produced by the Personal 
Social Services Research Unit.15 No data were available for inflation from 2014/2015 to 2015/2016 so it was assumed to be the same as 
between 2013/2014 and 2014/2015. The UK consumer price index for health services shows similar annual growth in this sector from 2014, 
which validates this assumption.
†The cost of management of MG/TV infection is assumed to be the same as the costs associated with management of CT infection.
‡These costs vary due to the difference in administrative staff time for patient registration if the patient is treated on the same day or on a 
subsequent visit.
§MSM have samples from three sites (urethral, rectal, pharyngeal) tested at the initial visit, whereas women and MSW typically have one 
sample taken.
BNF, British National Formulary; CT, Chlamydia trachomatis; MG, Mycoplasma genitalium; NAAT, nucleic acid amplification test; NG, Neisseria 
gonorrhoeae; PID, pelvic inflammatory disease; POC, point-of-care; TV, Trichomonas vaginalis.
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cost used for commissioning and cross-charging,18 was 
estimated using the draft 2015/2016 NHS tariff for first 
and follow-up GUM attendances. Fixed tariffs are not 
affected by how treatment is administered (oral/intra-
muscular) or the number of tests performed.
Costs of implementing a change in practice, including 
training costs, were not considered. However, the unit 
costs used for staff time, which were considered, do incor-
porate the cost of training courses.15 Costs associated with 
testing and treating other causes of lower genitourinary 
tract symptoms were not considered.
Utilities, measures of health-related quality of life, were 
used in calculating QALYs for the health states (asymp-
tomatic, symptomatic or awaiting test results) incorpo-
rated in the decision analytic framework (table 2).
scenario and sensitivity analysis
As well as the base-case analysis, 32 further scenarios were 
assessed deterministically, that is, where one or more key 
parameters were varied based on changing the assump-
tion of that parameter(s) while holding all others at 
the base-case level (see online supplementary table 3). 
Scenarios included: higher STI prevalence; lower sensi-
tivity and specificity of POCTs; differing microscopy use; 
cheaper POCTs and different LTFU rates.
We performed a second-order Monte Carlo probabilistic 
sensitivity analysis (PSA), consistent with best practice, to 
estimate base-case ICERs. We converted model inputs 
from discrete values to distributions. For cost inputs, we 
used a normal distribution and varied each cost by 20% 
for the SD. We correlated costs of POCTs against the least 
expensive option to ensure test costs would change equiv-
alently to the same degree with each simulation. For clin-
ical parameters, we used beta and normal distributions 
for probabilities and uniform distributions for test perfor-
mance. For utilities, normal distributions were used. The 
PSA included 5000 simulations and was performed using 
recommended procedures.19 Probabilities that strategies 
were cost-effective at a range of willingness-to-pay (WTP) 
thresholds per QALY gained were presented in cost-ef-
fectiveness acceptability curves (CEACs). CEACs were 
generated for each subgroup and the total population. 
Threshold costs for POCTs at which POC strategies would 
become cost-saving were calculated to the nearest £0.25.
results
Using microcosting, the estimated annual cost of testing 
and managing CT, NG, MG and TV infections in 965 988 
symptomatic individuals attending GUM was £113 058 655 
using SC. This was the cheapest strategy to clinical services, 
with POC strategies A, B and C being increasingly expen-
sive at £118 704 963 (5% increase), £124 842 003 (10.4% 
increase) and £125 313 136 (10.8% increase), respectively 
(table 3). The opposite was true when using tariff costs, 
with SC being the most expensive for commissioners of 
sexual healthcare at £172 364 138, and POC strategy C 
being the least expensive, at £145 912 757 (table 3).
Most of the total care pathway cost was the initial 
attendance cost. In SC, total pathway costs for women 
were £65 122 097, of this 93% (£60 432 050) were initial 
Table 3 The costs, QALYs, average time to cure, inappropriate treatment and follow-up visits in SC and three POC strategies 
for symptomatic people attending GUM services
Subgroup Strategy
Total costs 
(microcosting)
Total costs 
(tariff)
Total 
QALYs
Average time 
to cure (days)
Inappropriate 
treatments
Mean number 
of visits/
person
Return 
clinic 
visits*
Infected 
partners
PID cases 
in women
All SC £113 058 655 £172 364 138 146 532 4.3 258 395 1.3 328 726 1876 176
POC A £118 704 963 £151 956 910 146 656 2.3 109 135 1.1 143 205 1414 119
POC B £124 842 003 £152 288 107 146 626 2.1 200 865 1.2 146 216 1451 64
POC C £125 313 136 £145 912 757 146 867 1.1 23 260 1.1 88 259 1068 64
Women SC £65 122 097 £99 714 696 89 533 4.4 176 604 1.3 149 216 764 176
POC A £66 938 018 £88 960 028 89 584 2.4 76 322 1.1 51 446 524 119
POC B £69 853 645 £89 101 615 89 554 2.2 128 806 1.1 52 733 535 64
POC C £69 285 504 £85 008 982 89 718 1.1 1607 1.0 15 528 260 64
MSW SC £29 572 989 £46 813 874 39 342 4.3 54 860 1.4 93 507 459 –
POC A £29 995 704 £40 111 202 39 389 2.1 20 957 1.1 32 574 343 – 
POC B £31 717 478 £40 614 444 39 380 2.0 54 863 1.1 37 149 360 – 
POC C £31 373 674 £38 724 875 39 443 1.2 13 218 1.1 19 971 285 – 
MSM SC £18 363 569 £25 835 568 17 658 4.1 26 931 1.7 86 002 653 – 
POC A £21 771 241 £22 885 680 17 684 2.3 11 855 1.5 59 185 546 – 
POC B £23 270 880 £22 572 047 17 692 1.5 17 196 1.5 56 334 556 – 
POC C £24 653 958 £22 178 900 17 706 1.2 8436 1.5 52 760 524 – 
*Return clinic visit for results and treatment, a test of cure (routine for NG) or because they remain symptomatic.
GUM, genitourinary medicine; MSM, men-who-have-sex-with-men; MSW, men-who-have-sex-with-women; PID, pelvic inflammatory disease; POC, 
point-of-care; QALY, quality-adjusted life year; SC, standard care.
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attendance costs. For POC strategy C, total pathway costs 
for women were £69 285 504, of which 98% (£68 041 383) 
were initial attendance costs.
POC strategy C provided most benefits to the full 
cohort. POC strategies A, B and C increased QALYs by 
124, 94 and 335, respectively compared with SC (table 3 
and table 4). Time to cure was shorter and the number of 
total clinic visits, onward STI transmissions and PID cases 
were fewer in POC strategies than in SC. Compared with 
SC, POC strategy C resulted in 240 467 fewer clinic visits, 
808 fewer onward STI transmissions, 235 135 averted 
inappropriate treatments and 112 fewer cases of PID.
ICERs associated with the base-case model are presented 
in table 4. POC C highlights cost-effectiveness relative to 
other strategies yielding an ICER of £36 585 per QALY 
gained compared with SC when using microcosting 
estimates. When incorporating NHS tariff costing, this 
represents a potential cost-savings of £26 451 382 relative 
to current practice.
CEACs are presented in figure 2. Using microcosting, for 
a WTP of £30 000/QALY, the upper threshold adopted by 
the National Institute for Health and Care Excellence,20 
SC had a 50% probability of being cost-effective overall, a 
17% probability for women, a 2% probability for MSW and 
a 99% probability for MSM, relative to the POC strategies. 
For a WTP of £25 000, POC C dominates, that is, is cheaper 
and yields more benefits than the other POC strategies for 
the total cohort, women and MSW. For MSM, SC domi-
nates all strategies across the thresholds examined. For 
MSW, POC A had 65% probability of being cost-effective at 
a WTP threshold of £10 000 per QALY gained.
Results of 32 scenario analyses are summarised in 
online supplementary tables 4-7. The proportion of 
patients given presumptive treatment (scenarios 21–24) 
impacted costs hugely. When no presumptive treatment 
was given (scenario 21), the cost per QALY was £7339 
and £9092 more than SC for POC strategies B and C, 
respectively, while POC strategy A was dominated by SC. 
When all patients without a diagnosis were presumptively 
treated for CT, MG or TV, according to which infections 
had been ruled out (scenario 24), POC strategies A and C 
were dominated by SC and POC strategy B cost £64 300/
QALY more than SC.
When the utility score for being symptomatic was 10% 
less than base-case (scenario 25), cost per QALY was 
£15 627 more for POC strategy C than for SC. If micros-
copy was no longer used in POC strategies (scenario 13), 
cost per QALY was £16 204 and £29 594 more than SC for 
POC strategies B and C, respectively, while POC strategy 
A was dominated by SC.
Table 4 Cost differences for SC and POC strategies
Subgroup Comparison QALY difference
Microcosting Tariff costs
Cost difference
ICER
(£/QALY gained) Cost difference
ICER
(£/QALY gained)
All POC A vs SC 124 £5  646 309 £45 516 −£20 407 228 Cost-saving
POC B vs SC 94 £11  783 348 £125 197 −£20 076 031 Cost-saving
POC C vs SC 335 £12 254 482 £36 585 −£26 451 382 Cost-saving
POC B vs A −30 £6 137 039 Dominated £331 197 Dominated
POC C vs B 241 £471 133 £1956 −£6 375 350 Cost-saving
Women POC A vs SC 51 £1 815 921 £35 608 −£10 754 668 Cost-saving
POC B vs SC 21 £4 731 548 £222 568 −£10 613 081 Cost-saving
POC C vs SC 185 £4 163 407 £22 448 −£14 705 715 Cost-saving
POC B vs A −30 £2 915 627 Dominated £141 587 Dominated
POC C vs B 164 −£5 68 141 Cost-saving −£4 092 634 Cost-saving
MSW POC A vs SC 47 £4 22 715 £9005 −£6 702 672 Cost-saving
POC B vs SC 38 £2 144 488 £56 104 −£6 199 430 Cost-saving
POC C vs SC 102 £1 800 685 £17 724 −£8 088 999 Cost-saving
POC B vs A −9 £1 721 773 Dominated £503 242 Dominated
POC C vs B 63 −£343 804 Cost-saving -£1 889 570 Cost-saving
MSM POC A vs SC 26 £3 407 672 £130 508 −£2 949 888 Cost-saving
POC B vs SC 35 £4 907 312 £141 683 −£3 263 521 Cost-saving
POC C vs SC 48 £6 290 390 £131 319 −£3 656 668 Cost-saving
POC B vs A 9 £1 499 639 £175 909 −£313 633 Cost-saving
POC C vs B 13 £1 383 078 £104 258 −£393 147 Cost-saving
ICER, incremental cost-effectiveness ratios; MSW, men-who-have-sex-with-women; MSM, men-who-have-sex-with-men; POC, point-of-
care; QALY, quality-adjusted life year; SC, standard care.
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If MG and TV prevalence were as high as the estimated 
prevalence in the USA21 22 (scenario 2), cost per QALY 
was £20 530 and £25 548 more than SC for POC strate-
gies B and C, respectively, while POC strategy A was domi-
nated by SC. When POCTs were priced the same as the 
SC test (scenario 31), POC strategies B and C were cost-
saving (using microcosting).
Holding all other parameters constant using base-
case assumptions, POC strategies would be cost-saving 
compared with SC, if POCTs cost £19.25, £13.50 and 
£21.00, respectively for POCTs A, B and C.
DIsCussIOn
Principle findings
This study compared costs, benefits and cost-effective-
ness of a laboratory-based CT-NG NAAT, with three POC 
strategies for: A) CT-NG; B) CT-NG-MG and C) CT-NG-
MG-TV. Using our initial assumptions for the total popu-
lation using the microcosting approach to assess direct 
costs to healthcare services, each POC strategy cost more 
than SC, but yielded additional benefits. The proportion 
of patients given presumptive treatment and the cost of 
the POCT kit both impacted the costs hugely. Results 
indicated that different strategies would be cost-effective 
for different patient subgroups depending on the WTP 
threshold in place. POC strategy A was most cost-effective 
for MSW, POC strategy C for women and SC for MSM. 
Whether using different testing strategies on different 
patient groups would be practical or acceptable was 
beyond the scope of this research and requires further 
investigation. Different results were obtained when tariff 
reimbursement costs were used, with POC strategy C 
costing the least and providing the most benefits.
strengths and weaknesses
Our analysis has several strengths. This is the first study 
to compare the cost-effectiveness of the three different 
STI POC strategies with SC. Comparable and consistent 
methods were used to construct a model with inputs from 
multiple sources including published studies, published 
data (for costs), national surveillance data plus expert 
opinion. The model incorporated uncertainty in multiple 
input parameters by using a second-order Monte Carlo 
PSA and numerous scenarios were assessed in sensitivity 
analysis.
Potential limitations should be considered. While it is 
thought that most UK clinicians follow the BASHH guide-
lines for STI testing and treatment,9 23 there is diversity 
in the testing and management strategies employed to 
meet specific patient needs, both within and between 
clinics. This diversity, the paucity of published data on 
treatment pathways and gaps in treatment guidelines, 
made building a representative SC pathway problematic. 
There were few published data for some input parame-
ters, for example, the percentage of patients who are 
presumptively treated without a microbiological result, 
the percentage returning to clinics after initial treatment 
and the percentage of patients attending with symp-
toms—all parameters which are likely to vary somewhat 
between clinics. We tried to overcome this using different 
scenario analysis and by collecting data using an online 
survey for GUM clinicians, although from a small sample 
size. Data from the survey showed high variation between 
Figure 2 Cost-effectiveness acceptability curves (CEACs): point-of-care test (POCT) strategies vs standard care. MSM, men-
who-have-sex-with-men; MSW, men-who-have-sex-with-women; W, women.
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clinics for some parameters. For example, the percentage 
of patients attending with symptoms ranged from 0% 
to 90%. There were few published data on utilities and 
sexual behaviour while symptomatic with an STI, while 
waiting for test results and while being on treatment 
for an STI. Both qualitative and quantitative research is 
needed in this area to inform future health economic 
analyses and to understand preferences for and impact 
on patients of introducing POC testing.
The staffing and consumable cost data used in the 
model were average costs. In reality, different sites use 
staff of different grades and salaries to perform similar 
tasks and negotiate different costs for consumables, 
implying an inevitable variation in how cost-effective the 
different strategies would be for different sites.
The costs associated with long-term complications of 
STIs were not considered.24 This limitation means that 
the results are conservative, as the costs associated with 
SC are likely to be underestimated. However, the long-
term benefits for a single round of testing were thought 
to be very low and to not have a major impact on the 
magnitude of results.
Comparing the results with other studies, POC path-
ways generated some cost-savings, primarily because 
patients had fewer return visits. However, these did not 
outweigh the higher cost of the POCTs compared with 
laboratory-based NAATs when estimating total pathway 
costs. This means that if POC testing was used, there 
would be expected overall cost increases based on the 
analysis using the microcosting approach. This differs 
from previous modelling, in which a CT-NG POCT was 
cost-saving compared with laboratory testing.5 In the 
model by Turner et al, the cost of a POC attendance was 
£6.95 cheaper than the cost of an SC attendance since 
the asymptomatic POC pathway was redesigned. In our 
model, the cost of attendance for a symptomatic patient 
was the same whether samples were sent to a laboratory or 
performed in clinic, since all symptomatic clinic attendees 
would require examination and microscopy.
Implications for public health, clinicians and people using 
GuM services
POC strategy C significantly decreased the numbers of 
inappropriate antibiotics given compared with SC, with 
over 235 000 fewer inappropriate treatments. Many of 
these treatments are likely to include azithromycin, 
which when inappropriately given can encourage spread 
of macrolide antibiotic resistance in MG infections.6 
POC strategy C also increased costs for health providers 
while decreasing tariff costs for commissioners, unless the 
‘freed-up’ capacity enabled by POC strategy C was used 
for STI screening appointments and initial assessments 
for symptomatic people. Although this would likely have 
a positive impact on public health, given GUM services in 
England face increasing pressure on their services with 
>2 million new attendances annually,7 while local authori-
ties equally face fiscal pressures, this work demonstrates the 
potential tensions between different cost-consequences 
for procurers and providers and public health benefits 
when considering implementation of novel health tech-
nologies. While there are no triplex or quadruplex POC 
STI tests currently on the market, there is at least one 
multiplex STI POC assay in development.25
For people using GUM services, there are numerous 
benefits to POC testing compared with SC. People would 
need fewer clinic visits, saving them time and reducing 
LTFU and reducing their costs such as out-of-pocket 
expenses and productivity losses. Receiving a diagnosis 
at the initial attendance reduces anxiety compared with 
waiting for test results.26 A negative result from a multipa-
thogen POCT will support the development of clearer 
guidelines for clinicians, which could also reassure 
patients, particularly those with vague genital tract symp-
toms. Receiving effective treatment at initial attendance is 
likely to reduce the duration of symptoms and reproduc-
tive health sequelae.1 2
POCTs can also generate public health benefits from 
swifter diagnosis and treatment, for example, POC 
strategy C led to an estimated 43% fewer onward transmis-
sions of STIs compared with SC. The ability to diagnose 
or rule out specific infections at first attendance enables 
accurate treatment and reduces inappropriate antibiotic 
use, crucial for good antibiotic stewardship, the economic 
benefits of which are substantial and well documented.27
unanswered questions and future research
Although a rapid test for CT and NG is used in some 
GUM services, multipathogen configurations of CT-NG-
MG-TV POCTs are not currently available. As such, likely 
pathways for POC strategies had to be designed based 
on expert opinion. Published audits of GUM patient 
pathways would be a useful addition to the literature. To 
reduce uncertainty in economic analyses around STIs, 
further evidence is also needed on underlying STI preva-
lence and the risk of onward STI transmission.
Patient pathways and testing protocols vary between 
sites and different sites see different proportions of 
people from the three subgroups. As such, the costs of 
changing to a POC strategy will vary between sites as 
will the benefits and costs not considered in the model. 
Validated and easy to use computational tools for clinics 
and commissioners, which assess the economic impact of 
implementing any one of the POC strategies, using local 
population data, would increase understanding across 
stakeholders.
COnClusIOn
In conclusion, the results suggest that although potentially 
more expensive, a quadruplex test for CT-NG-MG-TV is 
more cost-effective than SC and the other testing strat-
egies assessed, providing the most additional benefits 
to patients. Cost implications are driven by the cost of 
POCTs and would vary somewhat in different geograph-
ical areas due to differences in the subgroup mix and the 
prevalence of the four STIs.
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